Discover investment opportunities in Oncology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Oncology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Oncology Stocks using our Smart AI Filter.
9 stocks found for "Oncology Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.63 Risk measure | ±35.0% Price volatility | 27.1 Valuation | 0.00% Annual yield | |||
0.45 Risk measure | ±25.0% Price volatility | 14.4 Valuation | 3.19% Annual yield | |||
0.37 Risk measure | ±19.7% Price volatility | 14.7 Valuation | 3.18% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.22 Risk measure | ±27.3% Price volatility | 15.0 Valuation | 2.83% Annual yield | |||
0.35 Risk measure | ±28.9% Price volatility | 6.7 Valuation | 5.29% Annual yield | |||
0.33 Risk measure | ±27.9% Price volatility | 8.6 Valuation | 4.00% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
1.25 Risk measure | ±58.8% Price volatility | -19.1 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do oncology stocks like MRK and BMY fare during economic downturns?
A: Oncology stocks such as MRK and BMY tend to demonstrate resilience in economic downturns due to the essential nature of their treatments. Demand for cancer therapies remains steady, offering potential stability for these companies as compared to more cyclical sectors.
Q: What competitive advantages do JNJ and PFE have in the oncology sector?
A: JNJ and PFE benefit from substantial R&D investments and broad patent portfolios, which provide a competitive edge in the oncology market. Their established presence and extensive pipelines may enhance their capabilities to innovate and capture market share.
Q: Are dividends from stocks like LLY and AMGN in the oncology sector reliable?
A: Companies such as LLY and AMGN offer dividends, but reliability can vary. Historically, these companies have demonstrated solid financial health, suggesting their dividends may be stable. However, investors should review payout ratios and financial statements for current insights.
Q: What should investors consider about the volatility of ROG in the oncology space?
A: ROG's stock may exhibit volatility due to factors like clinical trial results, regulatory approvals, and healthcare policy changes. Investors should consider these elements and the inherent risks in biotech to understand potential price fluctuations.
Q: How do AZN and GILD's pipelines impact their growth prospects in oncology?
A: AZN and GILD have robust pipelines, which some investors view as a key driver of growth. New approvals and oncology innovations can significantly boost revenues. Monitoring trial progress and regulatory updates is critical to assessing future performance prospects.
Q: What ESG factors could influence investments in companies like REGN in the oncology industry?
A: REGN's ESG factors, such as sustainable practices and ethical drug pricing, could affect investor decisions. Companies prioritizing environmental stewardship, social responsibility, and governance are increasingly attractive to ESG-conscious investors.
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last week.
Read more